Generics Industry Fails To Match Last Year’s Growth In First Quarter
Firms Including Sandoz, Teva And Amneal Struggle With Prior-Year Comparison
Executive Summary
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.